A single center pilot study. Spirometry, lung clearance index (LCI), maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) were measured at baseline (visit 1), after a month of IMT with ®POWERbreathe (visit 2), and at follow-up (visit 3).
The cohort included 27 patients (19 PCD, 8 CF); mean age 18.4 ± 9.8 years. After a month of IMT, there was a significant increase in MIP and MIP% (6.19-7.44, p = .015; and 81.85%-100.41%, p = .046, respectively), which was sustained at visit 3. Compliance ≥90% led to higher improvement in MIP. In sub-group analysis, improvement in MIP and MIP% remained significant for PCD patients (p = .026 and p = .049, respectively). No significant changes were found in spirometry, MEP or LCI.
IMT was well-tolerated and led to improved inspiratory muscle strength in PCD patients. The clinical implication of improved MIP should be further investigated. Larger, long-term studies are needed to evaluate long-term effects of IMT on pulmonary function, respiratory muscle strength, pulmonary exacerbations, and quality of life.
方法:单中心试点研究。肺活量测定,肺清除指数(LCI),最大吸气压力(MIP),和最大呼气压(MEP)测量在基线(第1次访问),在使用®POWER呼吸进行IMT一个月后(第2次访问),和随访(第3次访问)。
结果:该队列包括27例患者(19例PCD,8CF);平均年龄18.4±9.8岁。经过一个月的IMT,MIP和MIP%显著增加(6.19-7.44,p=0.015;81.85%-100.41%,分别为p=.046),在访问3时持续。合规性≥90%导致MIP有更高的改善。在分组分析中,PCD患者的MIP和MIP%改善仍然显著(分别为p=.026和p=.049).肺活量没有发现明显变化,MEP或LCI。
结论:在PCD患者中,IMT具有良好的耐受性,并导致吸气肌强度改善。改善MIP的临床意义有待进一步研究。较大,需要长期研究来评估IMT对肺功能的长期影响,呼吸肌力量,肺加重,和生活质量。